{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06178614",
            "orgStudyIdInfo": {
                "id": "CR109339"
            },
            "secondaryIdInfos": [
                {
                    "id": "2023-505358-16-00",
                    "type": "REGISTRY",
                    "domain": "EUCT number"
                },
                {
                    "id": "87890387STM1001",
                    "type": "OTHER",
                    "domain": "Janssen Research & Development, LLC"
                }
            ],
            "organization": {
                "fullName": "Janssen Research & Development, LLC",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study of JNJ-87890387 for Advanced Solid Tumors",
            "officialTitle": "A Phase 1 Study of JNJ-87890387, an Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 3 (ENPP3) x CD3 Bispecific Antibody, for Advanced Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-study-of-jnj-for-advanced-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-12-14",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-03-16",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-03-16",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-12-12",
            "studyFirstSubmitQcDate": "2023-12-12",
            "studyFirstPostDateStruct": {
                "date": "2023-12-21",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-15",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-17",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Janssen Research & Development, LLC",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to determine recommended phase 2 dose(s) (RP2Ds) of JNJ-87890387 and to determine the safety of JNJ-87890387 at the RP2D(s)."
        },
        "conditionsModule": {
            "conditions": [
                "Advanced Solid Tumors"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 140,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "JNJ-87890387",
                    "type": "EXPERIMENTAL",
                    "description": "In Part 1 (Dose escalation) participants will receive JNJ-87890387. The dose will be escalated sequentially until the recommended phase 2 dose (RP2D) regimen(s) have been identified. In Part 2 (Dose expansion), participants will receive JNJ-87890387 at the RP2D regimen(s) determined in Part 1.",
                    "interventionNames": [
                        "Drug: JNJ-87890387"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "JNJ-87890387",
                    "description": "JNJ-87890387 will be administered.",
                    "armGroupLabels": [
                        "JNJ-87890387"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Part 1: Number of Participants with Dose Limiting Toxicity (DLTs)",
                    "description": "Number of participants with DLTs will be reported. The DLTs are adverse events including certain high grade non-hematologic or hematologic toxicities, or toxicities meeting other specific criteria.",
                    "timeFrame": "Up to first 21 days after first dose"
                },
                {
                    "measure": "Part 1 and Part 2: Number of Participants with Adverse Events (AEs) by Severity",
                    "description": "An AE is any untoward medical occurrence in a clinical study participant administered an investigational or non-investigational product and it does not necessarily have a causal relationship with the investigational product. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0 with the exception of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome events (ICANS), which will be graded by American Society for Transplantation and Cellular Therapy (ASTCT) guidelines. Severity scale ranges from grade 1 (mild) to grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening and Grade 5= death related to adverse event.",
                    "timeFrame": "Up to 2 years 9 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Part 1 and Part 2: Serum Concentration of JNJ-87890387",
                    "description": "Serum concentration of JNJ-87890387 will be reported.",
                    "timeFrame": "Up to 2 years 9 months"
                },
                {
                    "measure": "Part 1 and Part 2: Maximum Observed Serum Concentration (Cmax) of JNJ-87890387",
                    "description": "Cmax is defined as maximum observed serum concentration of JNJ-87890387.",
                    "timeFrame": "Up to 2 years 9 months"
                },
                {
                    "measure": "Part 1 and Part 2: Time to Reach Maximum Observed Serum Concentration (Tmax) of JNJ-87890387",
                    "description": "Tmax is defined as the time to reach maximum observed serum concentration of JNJ-87890387.",
                    "timeFrame": "Up to 2 years 9 months"
                },
                {
                    "measure": "Part 1 and Part 2: Area Under the Curve from Time t1 to Time t2 (AUC[t1-t2]) of JNJ-87890387",
                    "description": "AUC(t1-t2) is defined as area under the serum concentration versus time curve from time t1 to time t2 of JNJ-87890387.",
                    "timeFrame": "Up to 2 years 9 months"
                },
                {
                    "measure": "Part 1 and Part 2: Area Under the Curve from Time Zero to Time tau (AUC[0-tau]) of JNJ-87890387",
                    "description": "AUC(0-tau) is defined as area under the serum concentration versus time curve from time 0 to time tau of JNJ-87890387.",
                    "timeFrame": "Up to 2 years 9 months"
                },
                {
                    "measure": "Part 1 and Part 2: Minimum Observed Serum Concentration (Cmin) of JNJ-87890387",
                    "description": "Cmin is defined as the minimum observed serum concentration of JNJ-87890387.",
                    "timeFrame": "Up to 2 years 9 months"
                },
                {
                    "measure": "Part 1 and Part 2: Accumulation Ratio of JNJ-87890387",
                    "description": "Accumulation ratio of JNJ-87890387 will be reported. The R is the accumulation ratio calculated as Cmax or AUC after multiple doses divided by Cmax or AUC after the first dose, respectively.",
                    "timeFrame": "Up to 2 years 9 months"
                },
                {
                    "measure": "Part 1 and Part 2: Number of Participants with Presence of Anti-JNJ-87890387 Antibodies",
                    "description": "Number of participants with presence of anti-JNJ-87890387 antibodies will be reported.",
                    "timeFrame": "Up to 2 years 9 months"
                },
                {
                    "measure": "Part 1 and Part 2: Objective Response Rate (ORR)",
                    "description": "ORR is defined as the percentage of participants with a best response of complete response or partial response according to Response Evaluation Criteria in Solid Tumors (RECIST) maintained for at least 4 weeks.",
                    "timeFrame": "Up to 2 years 9 months"
                },
                {
                    "measure": "Part 1 and Part 2: Duration of Response (DOR)",
                    "description": "DOR is defined as the duration from the date of initial documentation of a response to the date of first documented evidence of disease progression according to RECIST v. 1.1, or death due to any cause, whichever occurs first.",
                    "timeFrame": "Up to 2 years 9 months"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Part 1 and Part 2: Time to Response (TTR)",
                    "description": "TTR is defined for the responders as the time from the date of the first dose of JNJ-87890387 to the date of the first documented response.",
                    "timeFrame": "Up to 2 years 9 months"
                },
                {
                    "measure": "Part 1 and Part 2: Cancer Antigen (CA) 125 Response Rate",
                    "description": "CA 125 response rate is defined as the proportion of participants with ovarian cancer who achieved a partial response or complete response according to the Gynecologic Cancer Intergroup (GCIG) response criteria for CA 125, maintained for at least 4 weeks. A CA 125 response is defined as at least 50 percentage (%) reduction in CA 125 levels from a pretreatment sample which must be confirmed and maintained for at least 28 days.",
                    "timeFrame": "Up to 2 years 9 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Have histologically or cytologically confirmed, metastatic, or unresectable solid tumor of one of the following types: a) Renal cell cancer (RCC)-clear cell or papillary carcinoma; b) Endometrioid ovarian cancer c) Endometrioid uterine carcinoma; d) Colorectal adenocarcinoma (CRC); e) Lung adenocarcinoma\n* Have measurable or evaluable disease: Part 1- Either measurable or evaluable disease; Part 2- At least 1 measurable lesion per RECIST v1.1. Participants with ovarian cancer without a measurable lesion must have disease evaluable per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) or have cancer antigen (CA) 125 greater than (\\>) 2\\*upper limit of normal (ULN) during screening\n* All participants in Part 1 and Part 2 must consent to provide an archived tumor tissue sample at screening\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at screening\n* Be willing and able to adhere to the lifestyle restrictions specified in this protocol.\n\nExclusion Criteria:\n\n* Active Central Nervous System (CNS) involvement with the exception of locally treated brain metastases that are clinically stable and asymptomatic for \\> 2 weeks and who are off or receiving low-dose corticosteroid treatment (less than or equal to \\[\\<=\\]10 milligrams \\[mg\\] prednisone or equivalent) for at least 2 weeks prior to start of study treatment\n* Toxicity from prior anticancer therapy that has not resolved to Grade \\<=1 (except alopecia, vitiligo, Grade \\<=2 peripheral neuropathy, or endocrinopathies that are stable on hormone replacement)\n* History of Grade greater than or equal to (\\>=) 2 immune-related AE(s) with prior immunotherapy that led to discontinuation of previous immunotherapy with the exception of Grade 2 and Grade 3 immune-related AEs that responded to treatment and that did not recur following rechallenge. Endocrinopathies that are stable on hormone replacement therapy or that have resolved are allowed.\n* History of solid organ or hematologic stem cell transplantation\n* Any episode of partial or complete bowel obstruction requiring hospitalization within 30 days prior to first dose of study treatment",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Study Contact",
                    "role": "CONTACT",
                    "phone": "844-434-4210",
                    "email": "Participate-In-This-Study@its.jnj.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Janssen Research & Development, LLC Clinical Trial",
                    "affiliation": "Janssen Research & Development, LLC",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Start Midwest",
                    "status": "RECRUITING",
                    "city": "Grand Rapids",
                    "state": "Michigan",
                    "zip": "49546",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.96336,
                        "lon": -85.66809
                    }
                },
                {
                    "facility": "Sarah Cannon Research Institute",
                    "status": "RECRUITING",
                    "city": "Nashville",
                    "state": "Tennessee",
                    "zip": "37203",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 36.16589,
                        "lon": -86.78444
                    }
                },
                {
                    "facility": "Centre Leon Berard",
                    "status": "RECRUITING",
                    "city": "Lyon",
                    "zip": "69008",
                    "country": "France",
                    "geoPoint": {
                        "lat": 45.74848,
                        "lon": 4.84669
                    }
                },
                {
                    "facility": "Institut Gustave Roussy",
                    "status": "RECRUITING",
                    "city": "Villejuif",
                    "zip": "94805",
                    "country": "France",
                    "geoPoint": {
                        "lat": 48.7939,
                        "lon": 2.35992
                    }
                },
                {
                    "facility": "Hosp Univ Vall D Hebron",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "zip": "08035",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "Hosp. Univ. 12 de Octubre",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28041",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical-trials/transparency.\n\nAs noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",
            "url": "https://www.janssen.com/clinical-trials/transparency"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M20194",
                    "name": "Antibodies, Bispecific",
                    "relevance": "LOW"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}